Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates

Publication date

2020-07-21

Authors

Walser, M.
Rothenberger, S.
Hurdiss, Daniel LORCID 0000-0003-3834-5808ISNI 0000000476570907
Schlegel, A.
Calabro, V.
Fontaine, S.
Villemagne, D.
Paladino, Martina
Hospodarsch, T.
Neculcea, A.

Editors

Advisors

Supervisors

Document Type

/dk/atira/pure/researchoutput/researchoutputtypes/workingpaper/preprint
Open Access logo

License

cc_by_nc_nd

Abstract

Globally accessible therapeutics against SARS-CoV-2 are urgently needed. Here, we report the generation of the first anti-SARS-CoV-2 DARPin molecules with therapeutic potential as well as rapid large-scale production capabilities. Highly potent multivalent DARPin molecules with low picomolar virus neutralization efficacies were generated by molecular linkage of three different monovalent DARPin molecules. These multivalent DARPin molecules target various domains of the SARS-CoV-2 spike protein, thereby limiting possible viral escape. Cryo-EM analysis of individual monovalent DARPin molecules provided structural explanations for the mode of action. Analysis of the protective efficacy of one multivalent DARPin molecule in a hamster SARS-CoV-2 infection model demonstrated a significant reduction of pathogenesis. Taken together, the multivalent DARPin molecules reported here, one of which has entered clinical studies, constitute promising therapeutics against the COVID-19 pandemic.

Keywords

Citation

Walser, M, Rothenberger, S, Hurdiss, D L, Schlegel, A, Calabro, V, Fontaine, S, Villemagne, D, Paladino, M, Hospodarsch, T, Neculcea, A, Cornelius, A, Schildknecht, P, Matzner, M, Haenggi, M, Franchini, M, Kaufmann, Y, Schlegel, I, Iss, C, Loser, T, Mangold, S, Herzog, C, Schiegg, D, Reichen, C, Radom, F, Bosshart, A, Lehmann, A, Haeuptle, M A, Zuercher, A, Vagt, T, Sigrist, G, Straumann, M, Proba, K, Veitonmaki, N, Dawson, K M, Zitt, C, Mayor, J, Ryter, S, Lyoo, H, Wang, C, Li, W, Drulyte, I, Binz, H K, de Waal, L, Stittelaar, K J & Lewis, S 2020 'Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates' bioRxiv. https://doi.org/10.1101/2020.08.25.256339